Muhammet Halil Baltacioglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muhammet Halil Baltacioglu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Burak Demir
Department of Nuclear Medicine, Sanliurfa Mehmet Akif Inan Education and Research Hospital, Sanliurfa, Turkey
4 shared publications - Nuriye Özlem Küçük
Department of Nuclear Medicine, Ankara University Medical School, Ankara, Turkey
4 shared publications - Cigdem Soydal
Department of Nuclear Medicine, Ankara University Medical School, Ankara, Turkey
3 shared publications - Mine Araz
Department of Nuclear Medicine, Ankara University Medical School, Ankara, Turkey
3 shared publications - Diğdem Kuru Öz
Ankara University Faculty of Medicine, Department of Radiology, Ankara, Türkiye
2 shared publications Pelin Sahin Oguz
2 shared publications
Latest Publications
- 30 July 2026
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
Comparison of the prognostic value of 18F-fluorodeoxyglucose PET/MRI and PET/computed tomography in recurrent ovarian cancer
Purpose: Peritoneal metastases significantly affect prognosis in ovarian cancer. We aimed to compare the prognostic value of 18 F-fluorodeoxyglucose PET/computed tomography ( 18 F-FDG PET/CT) and 18 F-FDG PET/MRI performed for restaging in patients with suspected recurrence and elevated CA-125. Materials and Methods: Forty-five recurrent ovarian cancer patients who underwent same-session 18 F-FDG PET/CT followed by whole-abdomen 18 F-FDG PET/MRI for restaging were included from a previously published prospective cohort; patients were followed for overall survival (OS; median follow-up: 61.9 months). Kaplan–Meier and Cox regression analyses were performed. Results: 18 F-FDG PET/MRI detected peritoneal involvement more frequently than 18 F-FDG PET/CT (78% vs. 58%, P = 0.012) and yielded higher peritoneal cancer index (PCI) scores ( P < 0.001). During follow-up, 35 patients (77.8%) died, and the median OS was 27.7 months. On 18 F-FDG PET/CT, the number of peritoneal lesions ( P = 0.002), PCI score ( P = 0.004), and distant organ metastases ( P = 0.017) were significantly associated with OS. Peritoneal involvement showed clearer survival separation on 18 F-FDG PET/CT than on 18 F-FDG PET/MRI ( P = 0.046 vs. P = 0.222). For 18 F-FDG PET/MRI, the number of peritoneal lesions ( P = 0.038) and PCI score ( P = 0.005) were significantly associated with OS, whereas peritoneal involvement on 18 F-FDG PET/MRI was not associated with OS. Thus, binary PET/MRI positivity and quantitative PET/MRI-derived disease burden showed different prognostic associations. In addition, among 18 F-FDG PET/MRI-positive patients, OS did not differ significantly between those positive only on 18 F-FDG PET/MRI and those positive on both 18 F-FDG PET/MRI and 18 F-FDG PET/CT ( P = 0.246). In the multivariable Cox model including age and both imaging modalities simultaneously, only 18 F-FDG PET/CT-defined peritoneal lesion burden (>5 vs. ≤5 lesions) remained independently associated with OS [hazard ratio = 3.80, 95% confidence interval (CI) = 1.35–10.68, P = 0.012], whereas 18 F-FDG PET/MRI-defined lesion burden (>5 vs. ≤5 lesions) did not retain statistical significance (hazard ratio = 1.31, 95% CI = 0.53–3.25, P = 0.555). Conclusion: Although 18 F-FDG PET/MRI detected peritoneal metastases more frequently and yielded higher PCI scores, 18 F-FDG PET/CT-derived peritoneal lesion burden demonstrated stronger independent prognostic value. 18 F-FDG PET/CT appears sufficient for baseline prognostic stratification, whereas 18 F-FDG PET/MRI may still provide complementary value for anatomical localization, detection of small-volume disease, and treatment planning.
- 30 July 2026
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
Comparison of the prognostic value of 18F-fluorodeoxyglucose PET/MRI and PET/computed tomography in recurrent ovarian cancer
Purpose: Peritoneal metastases significantly affect prognosis in ovarian cancer. We aimed to compare the prognostic value of 18 F-fluorodeoxyglucose PET/computed tomography ( 18 F-FDG PET/CT) and 18 F-FDG PET/MRI performed for restaging in patients with suspected recurrence and elevated CA-125. Materials and Methods: Forty-five recurrent ovarian cancer patients who underwent same-session 18 F-FDG PET/CT followed by whole-abdomen 18 F-FDG PET/MRI for restaging were included from a previously published prospective cohort; patients were followed for overall survival (OS; median follow-up: 61.9 months). Kaplan–Meier and Cox regression analyses were performed. Results: 18 F-FDG PET/MRI detected peritoneal involvement more frequently than 18 F-FDG PET/CT (78% vs. 58%, P = 0.012) and yielded higher peritoneal cancer index (PCI) scores ( P < 0.001). During follow-up, 35 patients (77.8%) died, and the median OS was 27.7 months. On 18 F-FDG PET/CT, the number of peritoneal lesions ( P = 0.002), PCI score ( P = 0.004), and distant organ metastases ( P = 0.017) were significantly associated with OS. Peritoneal involvement showed clearer survival separation on 18 F-FDG PET/CT than on 18 F-FDG PET/MRI ( P = 0.046 vs. P = 0.222). For 18 F-FDG PET/MRI, the number of peritoneal lesions ( P = 0.038) and PCI score ( P = 0.005) were significantly associated with OS, whereas peritoneal involvement on 18 F-FDG PET/MRI was not associated with OS. Thus, binary PET/MRI positivity and quantitative PET/MRI-derived disease burden showed different prognostic associations. In addition, among 18 F-FDG PET/MRI-positive patients, OS did not differ significantly between those positive only on 18 F-FDG PET/MRI and those positive on both 18 F-FDG PET/MRI and 18 F-FDG PET/CT ( P = 0.246). In the multivariable Cox model including age and both imaging modalities simultaneously, only 18 F-FDG PET/CT-defined peritoneal lesion burden (>5 vs. ≤5 lesions) remained independently associated with OS [hazard ratio = 3.80, 95% confidence interval (CI) = 1.35–10.68, P = 0.012], whereas 18 F-FDG PET/MRI-defined lesion burden (>5 vs. ≤5 lesions) did not retain statistical significance (hazard ratio = 1.31, 95% CI = 0.53–3.25, P = 0.555). Conclusion: Although 18 F-FDG PET/MRI detected peritoneal metastases more frequently and yielded higher PCI scores, 18 F-FDG PET/CT-derived peritoneal lesion burden demonstrated stronger independent prognostic value. 18 F-FDG PET/CT appears sufficient for baseline prognostic stratification, whereas 18 F-FDG PET/MRI may still provide complementary value for anatomical localization, detection of small-volume disease, and treatment planning.
- 27 July 2026
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 65 (05) , 321-322
Detection of Brain Metastasis in Occult Medullary Thyroid Carcinoma Using ⁶⁸Ga-DOTATATE PET/CT: A Case Report
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor that may express somatostatin receptors, enabling imaging with ⁶⁸Ga-DOTATATE PET/CT. Brain metastases from MTC are extremely rare, particularly in the absence of an identifiable primary tumor. We present a 63-year-old male with occult MTC and elevated serum calcitonin levels (27 pg/mL). ⁶⁸Ga-DOTATATE PET/CT demonstrated focal tracer uptake in the right parietal lobe (SUVmax: 9.1), which was confirmed by brain MRI as a 7-mm enhancing lesion consistent with metastasis. This case highlights the value of ⁶⁸Ga-DOTATATE PET/CT in detecting unusual metastatic presentations in occult MTC.
- 27 July 2026
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 65 (05) , 321-322
Detection of Brain Metastasis in Occult Medullary Thyroid Carcinoma Using ⁶⁸Ga-DOTATATE PET/CT: A Case Report
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor that may express somatostatin receptors, enabling imaging with ⁶⁸Ga-DOTATATE PET/CT. Brain metastases from MTC are extremely rare, particularly in the absence of an identifiable primary tumor. We present a 63-year-old male with occult MTC and elevated serum calcitonin levels (27 pg/mL). ⁶⁸Ga-DOTATATE PET/CT demonstrated focal tracer uptake in the right parietal lobe (SUVmax: 9.1), which was confirmed by brain MRI as a 7-mm enhancing lesion consistent with metastasis. This case highlights the value of ⁶⁸Ga-DOTATATE PET/CT in detecting unusual metastatic presentations in occult MTC.
- 24 June 2026
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 61 (04) , 278-279
False-Positive Rib Lesion on Bone Scintigraphy and 68Ga-PSMA PET/CT: Fibrous Dysplasia Mimicking Metastasis
A 68-year-old man with recently diagnosed prostate adenocarcinoma (Gleason score 3+4=7; PSA 9.6 ng/mL) demonstrated focal increased uptake in the right sixth rib on both 99mTc-HDP bone scintigraphy and 68Ga-PSMA PET/CT, findings initially suggestive of a solitary rib metastasis ([Fig. 1]). Subsequently, surgical resection of the affected rib segment was performed, and histopathological examination confirmed fibrous dysplasia, thereby excluding metastatic disease. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein significantly overexpressed in prostate cancer cells, making it an ideal target for molecular imaging and theranostic applications [1]. However, accumulated clinical experience and evidence in the literature have demonstrated that PSMA ligand uptake is not specific for malignancy. Increased uptake has been described in various benign and physiological conditions, including celiac ganglia, healing fractures, Paget’s disease, and benign osteoblastic activity, potentially leading to false-positive interpretations [2] [3] [4]. Among benign bone pathologies, fibrous dysplasia (FD) is an uncommon skeletal disorder characterized by replacement of normal bone with fibro-osseous tissue. It accounts for approximately 5–7% of benign bone tumors and most commonly presents in a monostotic form [5] [6] [7]. Nevertheless, the presence of intense tracer uptake on functional imaging studies in the absence of malignancy is uncommon and represents a potential diagnostic pitfall. Several studies have documented focal or even intense uptake in fibrous dysplasia on both bone scintigraphy and PSMA PET, potentially mimicking metastatic disease [3] [8] [9] [10]. These cases highlight the diagnostic challenges posed by benign bone lesions demonstrating radiotracer avidity, particularly in oncologic patients in whom the threshold for suspecting metastasis is low. Unlike most previously published reports, which describe findings on a single imaging modality, our case demonstrated intense uptake on both bone scintigraphy and 68Ga-PSMA PET/CT. To the best of our knowledge, this case adds to the limited literature on histologically confirmed rib fibrous dysplasia with dual tracer positivity. This finding underscores the importance of careful image interpretation, especially in atypical locations, and supports the role of histopathological confirmation in cases with indeterminate imaging findings. Received: 25 February 2026 Accepted: 24 March 2026 Article published online: 24 June 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 24 June 2026
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 61 (04) , 278-279
False-Positive Rib Lesion on Bone Scintigraphy and 68Ga-PSMA PET/CT: Fibrous Dysplasia Mimicking Metastasis
A 68-year-old man with recently diagnosed prostate adenocarcinoma (Gleason score 3+4=7; PSA 9.6 ng/mL) demonstrated focal increased uptake in the right sixth rib on both 99mTc-HDP bone scintigraphy and 68Ga-PSMA PET/CT, findings initially suggestive of a solitary rib metastasis ([Fig. 1]). Subsequently, surgical resection of the affected rib segment was performed, and histopathological examination confirmed fibrous dysplasia, thereby excluding metastatic disease. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein significantly overexpressed in prostate cancer cells, making it an ideal target for molecular imaging and theranostic applications [1]. However, accumulated clinical experience and evidence in the literature have demonstrated that PSMA ligand uptake is not specific for malignancy. Increased uptake has been described in various benign and physiological conditions, including celiac ganglia, healing fractures, Paget’s disease, and benign osteoblastic activity, potentially leading to false-positive interpretations [2] [3] [4]. Among benign bone pathologies, fibrous dysplasia (FD) is an uncommon skeletal disorder characterized by replacement of normal bone with fibro-osseous tissue. It accounts for approximately 5–7% of benign bone tumors and most commonly presents in a monostotic form [5] [6] [7]. Nevertheless, the presence of intense tracer uptake on functional imaging studies in the absence of malignancy is uncommon and represents a potential diagnostic pitfall. Several studies have documented focal or even intense uptake in fibrous dysplasia on both bone scintigraphy and PSMA PET, potentially mimicking metastatic disease [3] [8] [9] [10]. These cases highlight the diagnostic challenges posed by benign bone lesions demonstrating radiotracer avidity, particularly in oncologic patients in whom the threshold for suspecting metastasis is low. Unlike most previously published reports, which describe findings on a single imaging modality, our case demonstrated intense uptake on both bone scintigraphy and 68Ga-PSMA PET/CT. To the best of our knowledge, this case adds to the limited literature on histologically confirmed rib fibrous dysplasia with dual tracer positivity. This finding underscores the importance of careful image interpretation, especially in atypical locations, and supports the role of histopathological confirmation in cases with indeterminate imaging findings. Received: 25 February 2026 Accepted: 24 March 2026 Article published online: 24 June 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 22 May 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (10) , e975-e976
Polyostotic Fibrous Dysplasia Mimicking Widespread Skeletal Metastases on 68Ga-PSMA PET/CT and Demonstrating a Superscan Pattern on Bone Scintigraphy
Fibrous dysplasia (FD) may demonstrate increased 68 Ga-PSMA uptake and mimic skeletal metastases in prostate cancer. We present a 63-year-old man with newly diagnosed prostate cancer who underwent 68 Ga-PSMA PET/CT for staging. Imaging revealed widespread skeletal uptake involving multiple regions, raising suspicion for diffuse metastatic disease. Bone scintigraphy demonstrated a superscan pattern. However, CT showed characteristic benign features, including ground-glass appearance, bone expansion, and preserved cortical integrity. Histopathologic examination confirmed fibrous dysplasia. This case highlights a potential diagnostic pitfall of 68 Ga-PSMA PET/CT and emphasizes the importance of correlating metabolic findings with CT morphology to avoid misinterpretation and overstaging.
- 22 May 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (10) , e975-e976
Polyostotic Fibrous Dysplasia Mimicking Widespread Skeletal Metastases on 68Ga-PSMA PET/CT and Demonstrating a Superscan Pattern on Bone Scintigraphy
Fibrous dysplasia (FD) may demonstrate increased 68 Ga-PSMA uptake and mimic skeletal metastases in prostate cancer. We present a 63-year-old man with newly diagnosed prostate cancer who underwent 68 Ga-PSMA PET/CT for staging. Imaging revealed widespread skeletal uptake involving multiple regions, raising suspicion for diffuse metastatic disease. Bone scintigraphy demonstrated a superscan pattern. However, CT showed characteristic benign features, including ground-glass appearance, bone expansion, and preserved cortical integrity. Histopathologic examination confirmed fibrous dysplasia. This case highlights a potential diagnostic pitfall of 68 Ga-PSMA PET/CT and emphasizes the importance of correlating metabolic findings with CT morphology to avoid misinterpretation and overstaging.
- 2 April 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (9) , e805-e806
Isolated Myocardial Metastases in a Neuroendocrine Tumor
Cardiac metastases from neuroendocrine tumors (NETs) are rare and usually occur in advanced metastatic disease. We present a 58-year-old man with a well-differentiated terminal ileum NET (grade 1, Ki-67 1%) who underwent 68 Ga-DOTATATE PET/CT for staging. The scan demonstrated intense uptake in the primary tumor and 2 incidental myocardial foci. Subsequent cardiac magnetic resonance imaging (CMR) revealed myocardial signal heterogeneity at corresponding locations, supporting the diagnosis of myocardial metastases. This case illustrates isolated myocardial involvement detected at initial staging of a well-differentiated NET and highlights the complementary role of somatostatin receptor–based PET/CT and CMR in detecting cardiac metastases.
- 2 April 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (9) , e805-e806
Isolated Myocardial Metastases in a Neuroendocrine Tumor
Cardiac metastases from neuroendocrine tumors (NETs) are rare and usually occur in advanced metastatic disease. We present a 58-year-old man with a well-differentiated terminal ileum NET (grade 1, Ki-67 1%) who underwent 68 Ga-DOTATATE PET/CT for staging. The scan demonstrated intense uptake in the primary tumor and 2 incidental myocardial foci. Subsequent cardiac magnetic resonance imaging (CMR) revealed myocardial signal heterogeneity at corresponding locations, supporting the diagnosis of myocardial metastases. This case illustrates isolated myocardial involvement detected at initial staging of a well-differentiated NET and highlights the complementary role of somatostatin receptor–based PET/CT and CMR in detecting cardiac metastases.
- Open Access
- 28 March 2026
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 40 (8) , 893-902
Prognostic impact of stage reclassification and N2 subclassification in the ninth edition of TNM classification for non-metastatic lung cancer
Purpose: This study aimed to evaluate whether the 9th edition of the tumor–node–metastasis (TNM) staging system more accurately reflects prognosis than the 8th edition in patients with non-metastatic lung cancer staged clinically using 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT). Material-methods: In this retrospective, two-center study, 1,590 patients diagnosed with lung cancer were initially evaluated. After excluding those with distant metastases at diagnosis, 529 patients (mean age: 65.9 ± 8.7 years) with stage I–III non-metastatic disease who underwent 18 F-FDG PET/CT between February 2017 and December 2023 were included. All patients were reclassified according to both the 8th and 9th editions of the TNM system, and changes in staging (upstaging, downstaging, or unchanged) were analyzed in relation to overall survival (OS). Results: The 5-year OS rates were 75.3% for cN0, 55.9% for cN1, 50.0% for cN2a, and 33.7% for cN2b. Although cN2a patients had higher OS compared to cN2b, the difference was not statistically significant ( p = 0.20). Importantly, patients with T1N2a tumors who were down-staged from stage IIIA to IIB showed significantly lower OS compared to those consistently classified as stage IIB ( p = 0.029), suggesting prognostic mismatch. In contrast, survival trends for patients down-staged from IIB to IIA (T1N1) and up-staged from IIIA to IIIB (T2N2b) were consistent with the revised TNM 9 classification, though without statistical significance ( p = 0.19 and p = 0.085, respectively). Conclusion: While several staging changes in the 9th TNM edition align with prognostic expectations, the downstaging of the T1N2a subgroup appears to be inconsistent with actual survival outcomes. These findings highlight the need for further large-scale, prospective, multicenter studies to validate the clinical reliability and implications of the revised staging system.
- 28 March 2026
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 40 (8) , 893-902
Open AccessPrognostic impact of stage reclassification and N2 subclassification in the ninth edition of TNM classification for non-metastatic lung cancer
Purpose: This study aimed to evaluate whether the 9th edition of the tumor–node–metastasis (TNM) staging system more accurately reflects prognosis than the 8th edition in patients with non-metastatic lung cancer staged clinically using 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT). Material-methods: In this retrospective, two-center study, 1,590 patients diagnosed with lung cancer were initially evaluated. After excluding those with distant metastases at diagnosis, 529 patients (mean age: 65.9 ± 8.7 years) with stage I–III non-metastatic disease who underwent 18 F-FDG PET/CT between February 2017 and December 2023 were included. All patients were reclassified according to both the 8th and 9th editions of the TNM system, and changes in staging (upstaging, downstaging, or unchanged) were analyzed in relation to overall survival (OS). Results: The 5-year OS rates were 75.3% for cN0, 55.9% for cN1, 50.0% for cN2a, and 33.7% for cN2b. Although cN2a patients had higher OS compared to cN2b, the difference was not statistically significant ( p = 0.20). Importantly, patients with T1N2a tumors who were down-staged from stage IIIA to IIB showed significantly lower OS compared to those consistently classified as stage IIB ( p = 0.029), suggesting prognostic mismatch. In contrast, survival trends for patients down-staged from IIB to IIA (T1N1) and up-staged from IIIA to IIIB (T2N2b) were consistent with the revised TNM 9 classification, though without statistical significance ( p = 0.19 and p = 0.085, respectively). Conclusion: While several staging changes in the 9th TNM edition align with prognostic expectations, the downstaging of the T1N2a subgroup appears to be inconsistent with actual survival outcomes. These findings highlight the need for further large-scale, prospective, multicenter studies to validate the clinical reliability and implications of the revised staging system.
- 19 March 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (9) , e787-e788
Right Temporal Variant Frontotemporal Dementia Presenting With Prosopagnosia
Right temporal variant frontotemporal dementia (rtvFTD) is a rare subtype of the FTD spectrum that typically presents with early deficits in person recognition rather than language impairment. We describe a 62-year-old man with progressive prosopagnosia and memory impairment whose T2-weighted MRI demonstrated atrophy in the right anterior temporal region. Subsequent 18 F-FDG PET revealed marked right temporal hypometabolism with additional involvement of the right frontal and anterior cingulate cortices, findings supported by quantitative SPM Z-score analysis. This structural-metabolic pattern is characteristic of rtvFTD, which primarily affects right temporal networks responsible for person recognition. Although right temporal atrophy has been documented in imaging studies of rtvFTD, detailed 18 F-FDG PET characterization remains scarce. This case contributes to the limited literature by providing a clear multimodal depiction of the characteristic metabolic signature of rtvFTD.
- 19 March 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (9) , e787-e788
Right Temporal Variant Frontotemporal Dementia Presenting With Prosopagnosia
Right temporal variant frontotemporal dementia (rtvFTD) is a rare subtype of the FTD spectrum that typically presents with early deficits in person recognition rather than language impairment. We describe a 62-year-old man with progressive prosopagnosia and memory impairment whose T2-weighted MRI demonstrated atrophy in the right anterior temporal region. Subsequent 18 F-FDG PET revealed marked right temporal hypometabolism with additional involvement of the right frontal and anterior cingulate cortices, findings supported by quantitative SPM Z-score analysis. This structural-metabolic pattern is characteristic of rtvFTD, which primarily affects right temporal networks responsible for person recognition. Although right temporal atrophy has been documented in imaging studies of rtvFTD, detailed 18 F-FDG PET characterization remains scarce. This case contributes to the limited literature by providing a clear multimodal depiction of the characteristic metabolic signature of rtvFTD.
- 17 July 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (12) , e712-e713
Solitary Scapular Metastasis as the Initial Presentation of Prostate Adenocarcinoma Detected by Ga-68 PSMA PET/CT
Prostate cancer commonly metastasizes to the skeleton, with multiple bones typically affected. Solitary metastasis in the appendicular skeleton, particularly in the scapula, is exceedingly rare. We present the case of a 75-year-old man with prostate adenocarcinoma, who initially presented with scapular bone metastasis detected using Ga-68 PSMA PET/CT. Imaging revealed intense uptake in a sclerotic lesion in the left scapula, suggesting a solitary metastasis.
- 17 July 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (12) , e712-e713
Solitary Scapular Metastasis as the Initial Presentation of Prostate Adenocarcinoma Detected by Ga-68 PSMA PET/CT
Prostate cancer commonly metastasizes to the skeleton, with multiple bones typically affected. Solitary metastasis in the appendicular skeleton, particularly in the scapula, is exceedingly rare. We present the case of a 75-year-old man with prostate adenocarcinoma, who initially presented with scapular bone metastasis detected using Ga-68 PSMA PET/CT. Imaging revealed intense uptake in a sclerotic lesion in the left scapula, suggesting a solitary metastasis.
- 27 May 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
68Ga DOTATATE PET/MR Imaging of Well-Differentiated Primary and Metastatic Liver Neuroendocrine Tumors
Purpose: To evaluate the potential of integrated multiparametric 68Ga DOTATATE PET/MR imaging for assessing liver lesions of well-differentiated neuroendocrine tumors (NETs) and to identify imaging parameters predictive of primary tumor localization. Patients and Methods: This retrospective study involves patients with well-differentiated NETs who underwent 68Ga DOTATATE PET/MRI between September 2018 and November 2024. Inclusion criteria required histopathologically proven NETs with 68Ga DOTATATE-avid liver metastases and complete multiparametric MRI sequences. PET and MRI-derived variables, including SUVmax, ADCmin, T/L ratios, and tumor volume (log-transformed tumor volume: LOGVOL), were analyzed. Linear mixed-effects models and logistic regression analyses were performed to identify relationships between imaging features and tumor characteristics. ROC analyses were conducted to evaluate the accuracy of primary tumor origin predictions. Results: Of 43 imaging sessions, 14 patients (7 male, 7 female; median age 59 y) with 181 lesions met the inclusion criteria. SUVmax was significantly correlated with LOGVOL and contrast enhancement parameters (eg, WOliver). Linear mixed-effects models revealed that LOGVOL and WOliver were independent predictors of SUVmax. In the binomial regression analysis, tumor precontrast T1 intensity, T/Lart, and T/Lven were significant factors in differentiation between pancreatic and gastrointestinal (GIS) NET metastases, with pancreatic tumors demonstrating higher T/Lart and GIS tumors exhibiting higher T/Lven and T1 intensity. Logistic regression achieved an AUC of 0.911, with a sensitivity of 86% and specificity of 76%. Conclusion: 68Ga DOTATATE PET/MRI effectively integrates metabolic and anatomical imaging for characterizing NET liver metastases. Parameters such as LOGVOL and WOliver independently predict SUVmax, while precontrast T1 intensity, T/Lart, and T/Lven assist in differentiating pancreatic from GIS NETs. These findings underscore the potential of 68Ga DOTATATE PET/MRI in personalized NET management and suggest avenues for further research to confirm these results.
- 27 May 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
68Ga DOTATATE PET/MR Imaging of Well-Differentiated Primary and Metastatic Liver Neuroendocrine Tumors
Purpose: To evaluate the potential of integrated multiparametric 68Ga DOTATATE PET/MR imaging for assessing liver lesions of well-differentiated neuroendocrine tumors (NETs) and to identify imaging parameters predictive of primary tumor localization. Patients and Methods: This retrospective study involves patients with well-differentiated NETs who underwent 68Ga DOTATATE PET/MRI between September 2018 and November 2024. Inclusion criteria required histopathologically proven NETs with 68Ga DOTATATE-avid liver metastases and complete multiparametric MRI sequences. PET and MRI-derived variables, including SUVmax, ADCmin, T/L ratios, and tumor volume (log-transformed tumor volume: LOGVOL), were analyzed. Linear mixed-effects models and logistic regression analyses were performed to identify relationships between imaging features and tumor characteristics. ROC analyses were conducted to evaluate the accuracy of primary tumor origin predictions. Results: Of 43 imaging sessions, 14 patients (7 male, 7 female; median age 59 y) with 181 lesions met the inclusion criteria. SUVmax was significantly correlated with LOGVOL and contrast enhancement parameters (eg, WOliver). Linear mixed-effects models revealed that LOGVOL and WOliver were independent predictors of SUVmax. In the binomial regression analysis, tumor precontrast T1 intensity, T/Lart, and T/Lven were significant factors in differentiation between pancreatic and gastrointestinal (GIS) NET metastases, with pancreatic tumors demonstrating higher T/Lart and GIS tumors exhibiting higher T/Lven and T1 intensity. Logistic regression achieved an AUC of 0.911, with a sensitivity of 86% and specificity of 76%. Conclusion: 68Ga DOTATATE PET/MRI effectively integrates metabolic and anatomical imaging for characterizing NET liver metastases. Parameters such as LOGVOL and WOliver independently predict SUVmax, while precontrast T1 intensity, T/Lart, and T/Lven assist in differentiating pancreatic from GIS NETs. These findings underscore the potential of 68Ga DOTATATE PET/MRI in personalized NET management and suggest avenues for further research to confirm these results.
- 29 April 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (1) , e48-e49
Plastron Appendicitis Mimicking a Malignant Adnexal Mass
Plastron appendicitis is a rare complication of acute appendicitis, characterized by localized and encapsulated inflammation within the surrounding tissues. It accounts for ∼4%–5% of all acute appendicitis cases. The mass-like appearance of plastron appendicitis can mimic various malignant pathologies, particularly those of the adnexal region. Due to its rarity, diagnosing plastron appendicitis can be challenging. Advanced imaging techniques, such as 18 F-FDG PET/CT, are crucial in differentiating it from other pathologies. In this case presentation, we aim to present the 18 F-FDG PET/CT and contrast-enhanced CT imaging findings of a patient with plastron appendicitis, which was initially suspected to be a malignant adnexal mass.
- 29 April 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (1) , e48-e49
Plastron Appendicitis Mimicking a Malignant Adnexal Mass
Plastron appendicitis is a rare complication of acute appendicitis, characterized by localized and encapsulated inflammation within the surrounding tissues. It accounts for ∼4%–5% of all acute appendicitis cases. The mass-like appearance of plastron appendicitis can mimic various malignant pathologies, particularly those of the adnexal region. Due to its rarity, diagnosing plastron appendicitis can be challenging. Advanced imaging techniques, such as 18 F-FDG PET/CT, are crucial in differentiating it from other pathologies. In this case presentation, we aim to present the 18 F-FDG PET/CT and contrast-enhanced CT imaging findings of a patient with plastron appendicitis, which was initially suspected to be a malignant adnexal mass.